{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:26Z","timestamp":1791928946199,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301347"],"award-info":[{"award-number":["82301347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Changsha City","award":["kq2208384"],"award-info":[{"award-number":["kq2208384"]}]},{"DOI":"10.13039\/501100004735","name":"Hunan Natural Science Foundation","doi-asserted-by":"crossref","award":["2023JJ41006"],"award-info":[{"award-number":["2023JJ41006"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Natural Science Foundation","doi-asserted-by":"crossref","award":["2023JJ40436"],"award-info":[{"award-number":["2023JJ40436"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55285-3","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:56:04Z","timestamp":1781272564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of gabapentin efficacy in patients with KCNQ2-developmental epileptic encephalopathy"],"prefix":"10.1038","volume":"16","author":[{"given":"Juan","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huazhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"55285_CR1","unstructured":"Miceli, F., Soldovieri, M. V., Weckhuysen, S., Cooper, E. & Taglialatela, M. KCNQ2-Related Disorders. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews((R)). Seattle (WA) (1993)."},{"key":"55285_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/jmedgenet-2020-107449","volume":"59","author":"S Boets","year":"2022","unstructured":"Boets, S. et al. Adult phenotype of KCNQ2 encephalopathy. J. Med. Genet. 59, 528\u2013535 (2022).","journal-title":"J. Med. Genet."},{"key":"55285_CR3","doi-asserted-by":"publisher","first-page":"11870","DOI":"10.1074\/jbc.M111.336511","volume":"287","author":"AP Stewart","year":"2012","unstructured":"Stewart, A. P. et al. The Kv7.2\/Kv7.3 heterotetramer assembles with a random subunit arrangement. J. Biol. Chem. 287, 11870\u201311877 (2012).","journal-title":"J. Biol. Chem."},{"key":"55285_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00018-016-2359-y","volume":"74","author":"DL Greene","year":"2017","unstructured":"Greene, D. L. & Hoshi, N. Modulation of Kv7 channels and excitability in the brain. Cell. Mol. Life Sci. 74, 495\u2013508 (2017).","journal-title":"Cell. Mol. Life Sci."},{"key":"55285_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/acn3.51316","volume":"8","author":"AT Berg","year":"2021","unstructured":"Berg, A. T., Mahida, S. & Poduri, A. KCNQ2-DEE: developmental or epileptic encephalopathy? Ann. Clin. Transl Neurol. 8, 666\u2013676 (2021).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"55285_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2023.03.004","volume":"144","author":"D Casas-Alba","year":"2023","unstructured":"Casas-Alba, D. et al. Relationship Between Epileptic Activity and Developmental Outcome in KCNQ2-Related Epilepsy. Pediatr. Neurol. 144, 11\u201315 (2023).","journal-title":"Pediatr. Neurol."},{"key":"55285_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/epi.12984","volume":"56","author":"T Pisano","year":"2015","unstructured":"Pisano, T. et al. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia 56, 685\u2013691 (2015).","journal-title":"Epilepsia"},{"key":"55285_CR8","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1007\/s00415-019-09404-y","volume":"266","author":"ZX Fang","year":"2019","unstructured":"Fang, Z. X. et al. KCNQ2 related early-onset epileptic encephalopathies in Chinese children. J. Neurol. 266, 2224\u20132232 (2019).","journal-title":"J. Neurol."},{"key":"55285_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.braindev.2020.08.015","volume":"43","author":"HJ Kim","year":"2021","unstructured":"Kim, H. J. et al. Clinical characteristics of KCNQ2 encephalopathy. Brain Dev. 43, 244\u2013250 (2021).","journal-title":"Brain Dev."},{"key":"55285_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cca.2022.03.001","volume":"530","author":"J Xiong","year":"2022","unstructured":"Xiong, J. et al. A novel KCNQ2 missense variant in non-syndromic intellectual disability causes mild gain-of-function of Kv7.2 channel. Clin. Chim. Acta. 530, 74\u201380 (2022).","journal-title":"Clin. Chim. Acta"},{"key":"55285_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/epi.14609","volume":"60","author":"C Gomis-Perez","year":"2019","unstructured":"Gomis-Perez, C. et al. Homomeric Kv7.2 current suppression is a common feature in KCNQ2 epileptic encephalopathy. Epilepsia 60, 139\u2013148 (2019).","journal-title":"Epilepsia"},{"key":"55285_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00424-020-02404-2","volume":"472","author":"P Nappi","year":"2020","unstructured":"Nappi, P. et al. Epileptic channelopathies caused by neuronal Kv7 (KCNQ) channel dysfunction. Pflugers Arch. 472, 881\u2013898 (2020).","journal-title":"Pflugers Arch."},{"key":"55285_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.nbd.2015.04.017","volume":"80","author":"A Abidi","year":"2015","unstructured":"Abidi, A. et al. A recurrent KCNQ2 pore mutation causing early onset epileptic encephalopathy has a moderate effect on M current but alters subcellular localization of Kv7 channels. Neurobiol. Dis. 80, 80\u201392 (2015).","journal-title":"Neurobiol. Dis."},{"key":"55285_CR14","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1038\/s41598-020-61697-6","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Identifying mutation hotspots reveals pathogenetic mechanisms of KCNQ2 epileptic encephalopathy. Sci. Rep. 10, 4756 (2020).","journal-title":"Sci. Rep."},{"key":"55285_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/epi.13676","volume":"58","author":"SB Mulkey","year":"2017","unstructured":"Mulkey, S. B. et al. Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain-of-function variants R201C and R201H. Epilepsia 58, 436\u2013445 (2017).","journal-title":"Epilepsia"},{"key":"55285_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105200","volume":"160","author":"MV Soldovieri","year":"2020","unstructured":"Soldovieri, M. V. et al. Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy. Pharmacol. Res. 160, 105200 (2020).","journal-title":"Pharmacol. Res."},{"key":"55285_CR17","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1124\/mol.118.112953","volume":"94","author":"RW Manville","year":"2018","unstructured":"Manville, R. W. & Abbott, G. W. Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels. Mol. Pharmacol. 94, 1155\u20131163 (2018).","journal-title":"Mol. Pharmacol."},{"key":"55285_CR18","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41401-023-01073-y","volume":"44","author":"GM Yang","year":"2023","unstructured":"Yang, G. M. et al. Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy. Acta Pharmacol. Sin. 44, 1589\u20131599 (2023).","journal-title":"Acta Pharmacol. Sin."},{"key":"55285_CR19","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1111\/epi.17627","volume":"64","author":"D Knight","year":"2023","unstructured":"Knight, D., Mahida, S., Kelly, M., Poduri, A. & Olson, H. E. Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy. Epilepsia 64, e143\u2013e147 (2023).","journal-title":"Epilepsia"},{"key":"55285_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1517\/14728222.7.6.737","volume":"7","author":"VK Gribkoff","year":"2003","unstructured":"Gribkoff, V. K. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin. Ther. Targets 7, 737\u2013748 (2003).","journal-title":"Expert Opin. Ther. Targets"},{"key":"55285_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1684\/epd.2021.1315","volume":"23","author":"A Nissenkorn","year":"2021","unstructured":"Nissenkorn, A. et al. Personalized treatment with retigabine for pharmacoresistant epilepsy arising from a pathogenic variant in the KCNQ2 selectivity filter. Epileptic Disord. 23, 695\u2013705 (2021).","journal-title":"Epileptic Disord."},{"key":"55285_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000096","volume":"2","author":"JJ Millichap","year":"2016","unstructured":"Millichap, J. J. et al. KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol. Genet. 2, e96 (2016).","journal-title":"Neurol. Genet."},{"key":"55285_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"55285_CR24","doi-asserted-by":"publisher","first-page":"122378","DOI":"10.1016\/j.lfs.2023.122378","volume":"339","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Improved classification and pathogenicity assessment by comprehensive functional studies in a large data set of KCNQ2 variants. Life Sci. 339, 122378 (2024).","journal-title":"Life Sci."},{"key":"55285_CR25","doi-asserted-by":"publisher","first-page":"e156314","DOI":"10.1172\/jci.insight.156314","volume":"7","author":"CG Vanoye","year":"2022","unstructured":"Vanoye, C. G. et al. High-throughput evaluation of epilepsy-associated KCNQ2 variants reveals functional and pharmacological heterogeneity. JCI Insight 7, e156314 (2022).","journal-title":"JCI Insight"},{"key":"55285_CR26","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1523\/JNEUROSCI.4423-14.2015","volume":"35","author":"F Miceli","year":"2015","unstructured":"Miceli, F. et al. Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. J. Neurosci. 35, 3782\u20133793 (2015).","journal-title":"J. Neurosci."},{"key":"55285_CR27","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1111\/epi.13601","volume":"58","author":"JJ Millichap","year":"2017","unstructured":"Millichap, J. J. et al. Infantile spasms and encephalopathy without preceding neonatal seizures caused by KCNQ2 R198Q, a gain-of-function variant. Epilepsia 58, e10\u2013e15 (2017).","journal-title":"Epilepsia"},{"key":"55285_CR28","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1523\/JNEUROSCI.3919-13.2014","volume":"34","author":"H Soh","year":"2014","unstructured":"Soh, H., Pant, R., LoTurco, J. J. & Tzingounis, A. V. Conditional deletions of epilepsy-associated KCNQ2 and KCNQ3 channels from cerebral cortex cause differential effects on neuronal excitability. J. Neurosci. 34, 5311\u20135321 (2014).","journal-title":"J. Neurosci."},{"key":"55285_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000515495","volume":"43","author":"K Springer","year":"2021","unstructured":"Springer, K., Varghese, N. & Tzingounis, A. V. Flexible Stoichiometry: Implications for KCNQ2- and KCNQ3-Associated Neurodevelopmental Disorders. Dev. Neurosci. 43, 191\u2013200 (2021).","journal-title":"Dev. Neurosci."},{"key":"55285_CR30","doi-asserted-by":"publisher","first-page":"RP91204","DOI":"10.7554\/eLife.91204.3","volume":"13","author":"TJ Abreo","year":"2025","unstructured":"Abreo, T. J. et al. Plural molecular and cellular mechanisms of pore domain KCNQ2 encephalopathy. Elife 13, RP91204 (2025).","journal-title":"Elife"},{"key":"55285_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1124\/jpet.123.001669","volume":"388","author":"G Varadi","year":"2024","unstructured":"Varadi, G. Mechanism of Analgesia by Gabapentinoid Drugs: Involvement of Modulation of Synaptogenesis and Trafficking of Glutamate-Gated Ion Channels. J. Pharmacol. Exp. Ther. 388, 121\u2013133 (2024).","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55285-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55285-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55285-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:02:42Z","timestamp":1787832162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55285-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55285"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55285-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Xiangya Hospital, Central South University (Approval ID: #) and conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript and agree to its submission for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26871"}}